Mortality and Institutionalisation Following de Novo Use of Rotigotine Patches in Hospitalised Patients with Parkinson’s Disease
Objective: Guidelines recommend use of rotigotine patches as an option if Parkinson’s patients are unable to take their usual oral medication, but this strategy has…Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Course of Impulse Control Disorder in People Living with Parkinson’s Disease: A Longitudinal Study on Dopamine Agonist Treatment
Objective: To compare the incidence and severity of ICDs among PwP treated with different DA, specifically examining their respective impacts on ICD onset and remission.…Medication Refractory Restless Legs Syndrome: Real-World Experience
Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…A case of Restless Abdominal Syndrome An Uncommon Variant of Restless Leg Syndrome
Objective: To identify restless abdominal syndrome as a potential cause of abdominal discomfort in patients presenting with discomfort in abdominal area which gets worse at…AI for Personalized Medication Management in Parkinson’s Disease
Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line
Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD
Objective: To identify EEG source level differences between patients with Parkinson's disease (PD) and associated impulse control disorders (ICD) and patients without ICD. Background: Previous…Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.
Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease
Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »